Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial

医学 内科学 微小残留病 急性淋巴细胞白血病 耐火材料(行星科学) 移植 胃肠病学 临床研究阶段 白血病 肿瘤科 临床试验 免疫学 淋巴细胞白血病 天体生物学 物理
作者
Tianyi Wang,Yanjing Tang,Jiaoyang Cai,Xinyu Wan,Shaoyan Hu,Xiaoxi Lu,Zhiwei Xie,Xiaohong Qiao,Hui Jiang,Jingbo Shao,Fan Yang,Hong Ren,Qing Cao,Juan Qian,Jian Zhang,Kang An,Jianmin Wang,Chengjuan Luo,Huanhuan Liang,Miao Yan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (9): 1670-1683 被引量:95
标识
DOI:10.1200/jco.22.01214
摘要

PURPOSE We determined the safety and efficacy of coadministration of CD19- and CD22-chimeric antigen receptor (CAR) T cells in patients with refractory disease or high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia. PATIENTS AND METHODS This phase II trial enrolled 225 evaluable patients age ≤ 20 years between September 17, 2019, and December 31, 2021. We first conducted a safety run-in stage to determine the recommended dose. After interim analysis of the first 30 patients treated (27 at the recommended dose) showing that the treatment was safe and effective, the study enrolled additional patients according to the study design. RESULTS Complete remission was achieved in 99.0% of the 194 patients with refractory leukemia or hematologic relapse, all negative for minimal residual disease. Their overall 12-month event-free survival (EFS) was 73.5% (95% CI, 67.3 to 80.3). Relapse occurred in 43 patients (24 with CD19 + /CD22 + relapse, 16 CD19 – /CD22 + , one CD19 – /CD22 – , and two unknown). Consolidative transplantation and persistent B-cell aplasia at 6 months were associated with favorable outcomes. The 12-month EFS was 85.0% (95% CI, 77.2 to 93.6) for the 78 patients treated with transplantation and 69.2% (95% CI, 60.8 to 78.8) for the 116 nontransplanted patients ( P = .03, time-dependent covariate Cox model). All 25 patients with persistent B-cell aplasia at 6 months remained in remission at 12 months. The 12-month EFS for the 20 patients with isolated testicular relapse was 95.0% (95% CI, 85.9 to 100), and for the 10 patients with isolated CNS relapse, it was 68.6% (95% CI, 44.5 to 100). Cytokine release syndrome developed in 198 (88.0%) patients, and CAR T-cell neurotoxicity in 47 (20.9%), resulting in three deaths. CONCLUSION CD19-/CD22-CAR T-cell therapy achieved relatively durable remission in children with relapsed or refractory B-acute lymphoblastic leukemia, including those with isolated or combined extramedullary relapse. [Media: see text]
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
牧百川发布了新的文献求助10
1秒前
普通人阿影完成签到,获得积分20
1秒前
1秒前
春风暮雪完成签到,获得积分10
2秒前
云槿完成签到,获得积分10
2秒前
2秒前
captainHc完成签到,获得积分10
2秒前
故渊丶发布了新的文献求助10
3秒前
小蘑菇的应助被沈恺恺采纳,获得10
3秒前
纯真少年完成签到,获得积分10
3秒前
4秒前
5秒前
5秒前
红雨灰衣发布了新的文献求助10
5秒前
可爱的函函的应助被沉沉叠叠采纳,获得10
6秒前
6秒前
博博要毕业完成签到 ,获得积分10
7秒前
dbguasy发布了新的文献求助10
7秒前
7秒前
晚霞跌落星河的应助被初景采纳,获得30
9秒前
缓慢念波完成签到,获得积分10
9秒前
沈恺恺完成签到,获得积分10
9秒前
kitty发布了新的文献求助10
10秒前
言淮完成签到,获得积分10
10秒前
科研通AI65的应助被Marshall采纳,获得10
10秒前
11秒前
张伟鸿完成签到,获得积分10
11秒前
高兴的采枫完成签到,获得积分10
11秒前
11秒前
12秒前
积极镜子完成签到 ,获得积分10
12秒前
牧百川发布了新的文献求助10
13秒前
13秒前
13秒前
Zhu发布了新的文献求助10
14秒前
FiFi完成签到 ,获得积分10
15秒前
16秒前
isabelle完成签到,获得积分10
16秒前
怪力花生完成签到,获得积分20
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183621
求助须知:如何正确求助?哪些是违规求助? 9572918
关于积分的说明 21828010
捐赠科研通 7780809
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558243
邀请新用户注册赠送积分活动 2480496